Oficiálny časopis Slovenskej kardiologickej spoločnosti,
Slovenskej hypertenziologickej spoločnosti a Slovenskej asociácie srdcových arytmií

Cardiology Letters 2020, 29(5):273-277

Medicína, COVID-19, kardiológia a rok 2020

Hatala R
Klinika kardiológie a angiológie NÚSCH, a. s. a LF SZU v Bratislave, Slovenská republika

Uverejnené: May 1, 2020  Zobraziť citáciu

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hatala R. Medicína, COVID-19, kardiológia a rok 2020. Cardiology Letters. 2020;29(5-6):273-277.
Share...
Stiahnuť citáciu
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Zobraziť celý článok

    Referencie

    1. Walsh B. The World Is Not Ready for the Next Pandemic. Time May 4 2017 https://time.com/magazine/us/4766607/may-15th2017-vol-189-no-18-u-s/
    2. Mehra MR, Desai SS, Ruschitzka F, Patel AN. RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020 May 22:S0140-6736(20)31180-6. doi: 10.1016/S0140-6736(20)31180-6. Epub ahead of print. Retraction in: Lancet. 2020 Jun 5;:null. Erratum in: Lancet. 2020 May 30; PMID: 32450107; PMCID: PMC7255293. Prejsť k pôvodnému zdroju...
    3. Hlavatý T, Krajčovičová A. Novel unorthodox strategies to reduce the case fatality rate of COVID-19 in high risk groups. Bratislava Medical Journal 2020; 121, No.7, ss. 462-465. Prejsť k pôvodnému zdroju...
    4. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020 Apr;8(4):e21. doi: 10.1016/S22132600(20)30116-8. Epub 2020 Mar 11. Erratum in: Lancet Respir Med. 2020 Jun;8(6):e54. Prejsť k pôvodnému zdroju...
    5. Vaduganathan M, Vardeny O, Michel T, et al. Renin-AngiotensinAldosterone System Inhibitors in Patients with Covid-19. N Engl J Med. 2020 Apr 23;382(17):1653-1659. doi: 10.1056/NEJMsr2005760. Prejsť k pôvodnému zdroju...
    6. Reynolds HR, Adhikari S, Pulgarin C, et al. Renin-AngiotensinAldosterone System Inhibitors and Risk of Covid-19. N Engl J Med. 2020 Jun 18;382(25):2441-2448. doi: 10.1056/NEJMoa2008975. Prejsť k pôvodnému zdroju...
    7. Ssentongo AE, Ssentongo P, Heilbrunn ES, et al. Renin-angiotensin-aldosterone system inhibitors and the risk of mortality in patients with hypertension hospitalised for COVID-19: systematic review and meta-analysis. Open Heart. 2020 Nov;7(2):e001353. doi: 10.1136/openhrt-2020-001353. Prejsť k pôvodnému zdroju...
    8. Flacco ME, Acuti Martellucci C, Bravi F, et al. Treatment with ACE inhibitors or ARBs and risk of severe/lethal COVID-19: a metaanalysis. Heart. 2020 Oct;106(19):1519-1524. doi: 10.1136/heartjnl-2020-317336. Prejsť k pôvodnému zdroju...
    9. Christiansen CF, Pottegård A, Heide-Jørgensen U, et al. SARSCoV-2 infection and adverse outcomes in users of ACE inhibitors and angiotensin-receptor blockers: a nationwide case-control and cohort analysis. Thorax. 2020 Dec 8:thoraxjnl-2020-215768. doi: 10.1136/thoraxjnl-2020-215768. Prejsť k pôvodnému zdroju...
    10. Hippisley-Cox J, Young D, Coupland C, et al. Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people. Heart. 2020 Oct;106(19):1503-1511. doi: 10.1136/heartjnl-2020-317393. Prejsť k pôvodnému zdroju...
    11. Ray KK, Wright RS, Kallend D, et al. For ORION-10 and ORION-11 Investigators. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med. 2020 Apr 16;382(16):1507-1519. doi: 10.1056/NEJMoa1912387. Prejsť k pôvodnému zdroju...
    12. Packer M, Anker SD, Butler J, et al.; EMPEROR-Reduced Trial Investigators. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020 Oct 8;383(15):1413-1424. doi: 10.1056/NEJMoa2022190. Prejsť k pôvodnému zdroju...
    13. O'Meara E, McDonald M, Chan M, et al. CCS/CHFS heart failure guidelines: clinical trial update on functional mitral regurgitation, SGLT2 inhibitors, ARNI in HFpEF, and tafamidis in amyloidosis. Can J Cardiol. 2020 Feb;36(2):159-169. doi: 10.1016/j.cjca.2019.11.036. Prejsť k pôvodnému zdroju...
    14. Maron DJ, Hochman JS, Reynolds HR, et al; ISCHEMIA Research Group. Initial Invasive or Conservative Strategy for Stable Coronary Disease. N Engl J Med. 2020 Apr 9;382(15):1395-1407. doi: 10.1056/NEJMoa1915922. Prejsť k pôvodnému zdroju...
    15. Wyse DG, Waldo AL, DiMarco JP, et al. Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002 Dec 5;347(23):1825-33. doi: 10.1056/NEJMoa021328. Prejsť k pôvodnému zdroju...
    16. Kirchhof P, Camm AJ, Goette A, et al.; EAST-AFNET 4 Trial Investigators. Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. N Engl J Med. 2020 Oct 1;383(14):1305-1316. doi: 10.1056/NEJMoa2019422. Prejsť k pôvodnému zdroju...

    Späť na obsah